The merging of experimental and human clinical trials will be decisive in the strategic design and application of NF-kB and NF-kB-miRNA-induced modulatory agents and drugs useful in the more efficacious treatment of the current AD epidemic. Here, NFKB1 is linked to Alzheimer disease.